Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lipid regulating drug interactions

The marked rises in statin levels and/or toxicity (rhabdomyolysis) probably occur because both the statin and eielosporin compete for the same metabolising enzyme, the cytochrome P450 isoenzyme CYP3A4. The extent of the interaction seems to depend on the relative affinities of the different statins for this isoenzyme, and also on whether they can be metabolised by alternative pathways. P-glycoprotein and other transporter proteins may also have a part to play, especially in the raised eielosporin levels seen with pravastatin. See Lipid regulating drugs , (p.l086) for more information about the metabolism of the statins. [Pg.1098]

See other pages where Lipid regulating drug interactions is mentioned: [Pg.114]    [Pg.900]    [Pg.1086]    [Pg.1094]    [Pg.1096]    [Pg.1105]    [Pg.1106]    [Pg.176]    [Pg.714]    [Pg.85]    [Pg.176]    [Pg.303]    [Pg.464]    [Pg.245]    [Pg.222]    [Pg.306]    [Pg.30]    [Pg.248]    [Pg.1]    [Pg.222]    [Pg.168]    [Pg.2074]    [Pg.515]    [Pg.1950]    [Pg.417]    [Pg.102]    [Pg.346]    [Pg.52]    [Pg.87]    [Pg.285]    [Pg.339]    [Pg.102]    [Pg.542]    [Pg.203]    [Pg.96]    [Pg.27]    [Pg.138]    [Pg.312]    [Pg.456]    [Pg.372]   
See also in sourсe #XX -- [ Pg.1086 ]



SEARCH



Drug-lipid interaction

Drugs regulation

Interaction lipids

Lipid regulators

© 2024 chempedia.info